Omalizumab as a corticosteroid‐sparing agent in the treatment of bullous pemphigoid

Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy is topical and systemic corticosteroids (CS) and immunosuppressors. As this pathology mainly in...

Descripción completa

Detalles Bibliográficos
Autores principales: Vassallo, Camilla, Somenzi, Anita, De Amici, Mara, Barruscotti, Stefania, Brazzelli, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078329/
https://www.ncbi.nlm.nih.gov/pubmed/36259470
http://dx.doi.org/10.1111/dth.15946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078329/
https://www.ncbi.nlm.nih.gov/pubmed/36259470
http://dx.doi.org/10.1111/dth.15946

Ejemplares similares